Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by topic
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by topic
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
FDA
Email alerts
FDA
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
Andrew A.
Davis
,
Vaibhav G.
Patel
Journal for ImmunoTherapy of Cancer
Dec 2019,
7
(1)
278;
DOI:
10.1186/s40425-019-0768-9
Special collections
COVID-19
(24)
Editor's choice
JITC
Basic Tumor Immunology
(304)
Case Reports
(176)
Clinical Trials Monitor
(14)
Clinical/Translational Cancer Immunotherapy
(561)
Commentary/Editorials
(100)
COVID-19 and Cancer Immunotherapy
(9)
Emerging Immunotherapeutic Agents
(5)
Guidelines and Consensus Statements
(33)
Guidelines and Consensus Statements
(24)
Immune Cell Therapies and Immune Cell Engineering
(72)
Immune Checkpoints - Beyond PD-1
(8)
Immune Checkpoints Beyond PD-1 Series
(8)
Immune Monitoring Technology Primers
(12)
Immunotherapy Biomarkers
(214)
Microbial-Based Cancer Immunotherapy
(4)
Oncolytic and Local Immunotherapy
(55)
Reviews
(163)
Open access
(1850)
Press releases
